Arvinas, IncARVN
Recorded
Arvinas, Inc Wells Fargo 21st Annual Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
PeriodFY 0Duration35 min
Key takeaways
- Arvinas has successfully brought its first product, VEP, to market through a partner company and is now focusing on clinical data from its pipeline programs.
- The company currently has four programs in the clinic: ARV393 (BCL6 degrader in hematology), an SBMA program targeting Kennedy's disease, ARV102 (LARC2 degrader for neurodegeneration), and an HPK1 degrader (6723) as their first immuno-oncology program.
- ARV393 is in a phase one dose escalation study with initial clinical data expected by the end of the year, focusing on T-cell lymphoma patients, with B-cell lymphoma data expected in 2027.
- The SBMA program is in phase one with data expected in the first half of next year, including healthy volunteers and patients.
- ARV102 has completed a phase one study in Europe and is undergoing regulatory discussions in the US, Europe, and Japan, with additional biomarker data to be presented next month at MDS.
- The HPK1 degrader program has just begun clinical trials, with data expected by the end of next year or so.
- Arvinas has cash runway guidance into the second half of 2028, allowing it to reach key clinical milestones comfortably.
- Management is focused on efficient investment and partnering selectively, exemplified by the G12D degrader program which will only progress with a partner.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Keep exploring